You are here: Industry Insights > Prostate Cancer

News List

Researchers find CD38-targeting drugs may show promise against prostate cancer pharmatimes
May 11, 2021
A new study suggests that drugs which target the CD38 protein molecule may show promise against prostate cancer by ‘reawakening’ the body’s immune response against this tumour type.
EC approves Xtandi™ for third prostate cancer indication europeanpharmaceuticalreview
May 07, 2021
Xtandi™ (enzalutamide) was approved for metastatic hormone-sensitive prostate cancer after it reduced the risk of radiographic progression or death by 61 percent in a trial.
Alchemab to collaborate with AstraZeneca on prostate cancer research pharmatimes
May 07, 2021
Cambridge-based biotech company Alchemab has announced a new collaboration with British pharma AstraZeneca (AZ), aiming to accelerate research for prostate cancer.
Mount Sinai Hospital in New York joins RhoVac's Phase IIb Study in Prostate Cancer prnasia
April 22, 2021
RhoVac AB, a Swedish cancer immunotherapy company, announces, April 21st 2021, that the prestigious Mount Sinai hospital in New York is initiated as the latest addition to US trial centres in RhoVac's clinical phase IIb study, "BRaVac", in prostate cancer
Immunotherapy vaccine shows promise in prostate cancer patients europeanpharmaceuticalreview
March 31, 2021
The multi-targeted hAd5 immunotherapy vaccine was found to be safe and showed initial signs of efficacy in patients with advanced metastatic castration-resistant prostate cancer.
NICE rejects AZ’s Lynparza for metastatic prostate cancer pharmatimes
March 10, 2021
The UK’s National Institute for Health and Care Excellence’s (NICE) appraisal committee has chosen not to recommend AstraZeneca’s (AZ) PARP inhibitor Lynparza for BRCA-positive metastatic prostate cancer.
First patient dosed with therapeutic prostate cancer vaccine europeanpharmaceuticalreview
February 20, 2021
The trial will evaluate the safety, tolerability and immunogenicity of Ultimovacs’ prostate cancer-specific therapeutic TET-based vaccine.
Erleada drug combination extends progression-free survival in prostate cancer trial europeanpharmaceuticalreview
February 10, 2021
In the Phase III ACIS study, prostate cancer patients treated with a combination of Erleada® and Zytiga® plus prednisone were less likely to die than participants receiving Zytiga and prednisone.
FDA Approves ORGOVYX for Advanced Prostate Cancer americanpharmaceuticalreview
January 15, 2021
The U.S. Food and Drug Administration (FDA) approved ORGOVYX (relugolix) for the treatment of adult patients with advanced prostate cancer.
ICR researchers identify potential new treatment for drug-resistant prostate cancer pharmatimes
January 13, 2021
Researchers from The Institute of Cancer Research, London (ICR) and the Royal Marsden NHS Foundation Trust have revealed the mechanism of action for a ‘promising’ new prostate cancer treatment.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page